India’s indigenous COVID-19 vaccine candidate, COVAXIN, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) has received the nod for Phase-3 clinical trials in the country. The Subject Expert Committee which functions under the drug regulator Drug Controller General of India (DCGI) has given approval for the last phase of clinical trials with certain conditions.
In the Third Phase of trials, which is proposed to begin in the first week of next month, the potential vaccine candidate will be tested on over 28 thousand people aged 18 years and above. These tests will be conducted across 10 states and 19 sites including Delhi, Mumbai, Patna and Lucknow among others.
Besides, Bharat Biotech’s COVAXIN, another indigenously developed vaccine candidate by Zydus Cadila Limited is also in Phase -2 of human clinical trials.